MXPA05007612A - Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares. - Google Patents

Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.

Info

Publication number
MXPA05007612A
MXPA05007612A MXPA05007612A MXPA05007612A MXPA05007612A MX PA05007612 A MXPA05007612 A MX PA05007612A MX PA05007612 A MXPA05007612 A MX PA05007612A MX PA05007612 A MXPA05007612 A MX PA05007612A MX PA05007612 A MXPA05007612 A MX PA05007612A
Authority
MX
Mexico
Prior art keywords
carnitine
treatment
grams
day
cardiovascular diseases
Prior art date
Application number
MXPA05007612A
Other languages
English (en)
Spanish (es)
Inventor
Koverech Aleardo
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MXPA05007612A publication Critical patent/MXPA05007612A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05007612A 2003-04-17 2004-03-03 Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares. MXPA05007612A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000178A ITRM20030178A1 (it) 2003-04-17 2003-04-17 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/IT2004/000107 WO2004091602A1 (en) 2003-04-17 2004-03-03 Use of l-carnitine for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
MXPA05007612A true MXPA05007612A (es) 2005-09-30

Family

ID=29765768

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007612A MXPA05007612A (es) 2003-04-17 2004-03-03 Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.

Country Status (11)

Country Link
US (1) US20060052450A1 (enExample)
EP (1) EP1613301A1 (enExample)
JP (1) JP2006523685A (enExample)
KR (1) KR20050121196A (enExample)
CN (2) CN101467992A (enExample)
AU (2) AU2004229256A1 (enExample)
BR (1) BRPI0406552A (enExample)
CA (1) CA2508636A1 (enExample)
IT (1) ITRM20030178A1 (enExample)
MX (1) MXPA05007612A (enExample)
WO (1) WO2004091602A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040346A1 (it) * 2004-07-13 2004-10-13 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.
US20070260674A1 (en) * 2006-05-02 2007-11-08 Research In Motion Limited Push framework for delivery of dynamic mobile content
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
EP2353596A1 (en) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
WO2012150146A1 (en) 2011-05-03 2012-11-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of lipid metabolism disorders
CN114073705A (zh) * 2020-08-14 2022-02-22 常州高新技术产业开发区三维工业技术研究所有限公司 一种降尿酸药物组合物及其应用
CN112180013B (zh) * 2020-09-29 2022-11-15 上海脉示生物技术有限公司 用于心肌梗死诊断的肠道微生物代谢标志物组合物及其检测方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS531812B2 (enExample) * 1972-12-07 1978-01-23
WO2000030637A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia

Also Published As

Publication number Publication date
CA2508636A1 (en) 2004-10-28
EP1613301A1 (en) 2006-01-11
ITRM20030178A0 (it) 2003-04-17
AU2010202396A1 (en) 2010-07-01
KR20050121196A (ko) 2005-12-26
ITRM20030178A1 (it) 2004-10-18
US20060052450A1 (en) 2006-03-09
AU2004229256A1 (en) 2004-10-28
CN1717232A (zh) 2006-01-04
WO2004091602A1 (en) 2004-10-28
JP2006523685A (ja) 2006-10-19
BRPI0406552A (pt) 2005-12-20
CN101467992A (zh) 2009-07-01

Similar Documents

Publication Publication Date Title
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
BRPI0509139A (pt) composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
EP1369119B1 (en) Il-12 expression controlling agents
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
NO20082672L (no) Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon
MXPA05007612A (es) Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.
ZA200609266B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin
CA2403994A1 (en) Nasal administration of agents for the treatment of gastroparesis
CA2632207C (en) Use of calcitonin for the treatment of ra
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
ES2312657T3 (es) Utilizacion de desoxipeganina en el tratamiento de la depresion clinica.
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
DE60326262D1 (de) Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden
JP2015500836A5 (enExample)
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
RU2002111257A (ru) Способ лечения больных с ишемическим инсультом
SI1773314T1 (sl) Uporaba L-karnitina za zdravljenje kardiovaskularnih bolezni
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
RU2005102282A (ru) Способ лечения тревожно-депрессивных расстройств и вегетативного дисбаланса у больных острым инфарктом миокарда
CY1114250T1 (el) Ακετυλ l-καρνιτινη για την προληψη της επιπονης περιφερικης διαβητικης νευροπαθειας
RU2002122034A (ru) Способ коррекции метаболических, иммунологических и дисбиотических нарушений в раннем послеоперационном периоде у больных, перенесших различные операции по поводу рака желудка
Serracino Inglott et al. Prevalence and drug treatment of the Parkinsonian syndrome in Malta
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment

Legal Events

Date Code Title Description
FG Grant or registration